EFFICACY AND SAFETY OF DASATINIB VS. IMATINIB IN LATIN AMERICAN SUBPOPULATION FROM THE DASISION TRIAL IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP)

被引：0
|
作者：
Enrico, A. [1 ]
Milone, J. [1 ]
Moiraghi, B. [2 ]
Casanova, L. [3 ,4 ]
Undurraga, M. S. [5 ]
Olivera, L. Enciso [6 ,7 ]
Bullorsky, E. [8 ]
Navarro Cabrera, J. [9 ]
Pagnano, K. [10 ]
De Riz, M. [11 ]
Pavlovsky, C. [12 ]
机构：
[1] Hosp Italiano La Plata, La Plata, Buenos Aires, Argentina
[2] Hosp JM Ramos Mejia, Caba, Argentina
[3] Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima, Peru
[4] Clin Oncol Miraflores, Dept Med Oncol, Lima, Peru
[5] Hosp Salvador, Santiago, Chile
[6] Inst Nacl Cancerol Bogota, Bogota, Colombia
[7] Univ Nacl Colombia, Bogota, Colombia
[8] Hosp Britanico Buenos Aires, Caba, Argentina
[9] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[10] Univ Estadual Campinas, Hemoctr Unicamp, Campinas, SP, Brazil
[11] Bristol Myers Squibb, Dept Med, Buenos Aires, DF, Argentina
[12] FUNDALEU, Caba, Argentina
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1119
引用
收藏
页码：446 / 447
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF DASATINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): EUROPEAN SUBPOPULATION ANALYSIS OF THE PHASE 3 DASISION TRIAL
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Stegelmann, F.
    Steegmann, J.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 75 - 75
  • [2] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [3] Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
    Chuah, Charles T.
    Nakamae, Hirohisa
    Shen, Zhixiang X.
    Bradley-Garelik, M. Brigid
    Kim, Dong-Wook
    LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 2093 - 2100
  • [4] Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial
    Khoury, H. Jean
    Cortes, Jurge E.
    Kantarjian, Hagop
    Baccarani, Michele
    Shah, Neil P.
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Hochhaus, Andreas
    BLOOD, 2010, 116 (21) : 1401 - 1401
  • [5] Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION
    Mauro, Michael J.
    Cortes, Jorge E.
    Hochhaus, Andreas
    Shah, Neil P.
    Atallah, Ehab
    Abaskharoun, Mena
    Sy, Oumar
    Saglio, Giuseppe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S14 - S15
  • [6] 5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION
    Hochhaus, A.
    Jabbour, E.
    Kantarjian, H.
    Guilhot, F.
    Kota, V.
    Hughes, T. P.
    Shelat, S.
    Li, L.
    Cortes, J. E.
    HAEMATOLOGICA, 2017, 102 : 433 - 433
  • [7] Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION
    Cortes, Jorge E.
    Hochhaus, Andreas
    Kantarjian, Hagop
    Guilhot, Francois
    Kota, Vamsi
    Hughes, Timothy P.
    Shelat, Suresh
    Sy, Oumar
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S308 - S309
  • [8] Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial.
    Guilhot, Francois
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 946 - 947
  • [9] Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION
    Mauro, Michael J.
    Cortes, Jorge E.
    Hochhaus, Andreas
    Shah, Neil P.
    Atallah, Ehab L.
    Abaskharoun, Mena
    Sy, Oumar
    Saglio, Giuseppe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S312 - S313
  • [10] ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION
    Saglio, G.
    Cortes, J. E.
    Hochhaus, A.
    Shah, N. P.
    Atallah, E. L.
    Abaskharoun, M.
    Li, L.
    Mauro, M. J.
    HAEMATOLOGICA, 2017, 102 : 436 - 437
12345